Northwire Canada EditionMonday, October 19, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4169.90 −0.3% SILVER 57.40 +0.2% COPPER 6.53 −0.6% OIL 97.56 −1.5% PALLADIUM 1124.25 +0.5% SAGE 0.110 +0.0% REC 0.050 +0.0% NICN 0.125 +8.7% TRX 1.48 −2.0% VLC 0.215 +2.4% TIGR 0.640 +3.2% TUO 1.42 −0.7% SVG 0.125 +0.0% VCU 1.02 +0.0% MACK 3.17 +2.3% COSA 0.380 −3.8% WGLD 0.130 +0.0% OSM 0.025 +0.0% TOM 0.145 +3.6% ALS 56.00 −1.0% FMAN 0.300 −1.6% GOLD 4169.90 −0.3% SILVER 57.40 +0.2% COPPER 6.53 −0.6% OIL 97.56 −1.5% PALLADIUM 1124.25 +0.5% SAGE 0.110 +0.0% REC 0.050 +0.0% NICN 0.125 +8.7% TRX 1.48 −2.0% VLC 0.215 +2.4% TIGR 0.640 +3.2% TUO 1.42 −0.7% SVG 0.125 +0.0% VCU 1.02 +0.0% MACK 3.17 +2.3% COSA 0.380 −3.8% WGLD 0.130 +0.0% OSM 0.025 +0.0% TOM 0.145 +3.6% ALS 56.00 −1.0% FMAN 0.300 −1.6%
Financings

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

By The Northwire Desk — AI Analysis Oct 20, 2025 · 08:30 QNTM · 19.85 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • The final tranche of 53,147 warrants issued to hedge funds and investment funds expired at 5 pm EST.
  • Quantum BioPharma reaffirmed October 27, 2025 as the record date for distributing one‑for‑one CVRs to holders of its Class B Subordinate Voting Shares.
  • Each CVR entitles holders to a pro‑rata share of 10%–50% of net proceeds recovered from litigation against CIBC World Markets, RBC Dominion Securities and others, subject to receipt of qualifying proceeds.

Key Details

  • Warrant Expiration: 53,147 warrants (originally part of a pre‑reverse split issuance of 3,454,543 warrants) expired; this was the last tranche issued to hedge funds/investment funds.
  • Record Date for CVR Distribution: October 27, 2025 confirmed as the record date for one‑for‑one CVR allocation to Class B Subordinate Voting Shareholders.
  • CVR Terms:
  • Non‑transferable, non‑assignable; no exchange listing.
  • No voting rights or interest; redeemable only for cash upon receipt of qualifying net proceeds from litigation.
  • Entitles holder to a minimum of 10% and up to 50% of the net proceeds recovered by the company in the lawsuit.
  • Litigation Background: Claims stock price manipulation and spoofing; seeks damages exceeding USD $700 million against CIBC World Markets, RBC Dominion Securities, and others.
  • Payment Contingency: CVR payments will occur only if and when the company receives net proceeds from a settlement or final, non‑appealable judgment; no guarantee of receipt or payment.
  • Use of Proceeds: Not applicable – CVRs are funded solely from litigation recoveries after deduction of fees, expenses, and costs.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other